Cas:1256355-24-4 (6-(Dimethylamino)pyridin-3-yl)boronic acid hydrate manufacturer & supplier

We serve Chemical Name:(6-(Dimethylamino)pyridin-3-yl)boronic acid hydrate CAS:1256355-24-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(6-(Dimethylamino)pyridin-3-yl)boronic acid hydrate

Chemical Name:(6-(Dimethylamino)pyridin-3-yl)boronic acid hydrate
CAS.NO:1256355-24-4
Synonyms:[6-(dimethylamino)pyridin-3-yl]-hydroxyboron
Molecular Formula:C7H11BN2O
Molecular Weight:149.98600
HS Code:2933399090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:36.36000
Exact Mass:150.09600
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like [6-(dimethylamino)pyridin-3-yl]-hydroxyboron chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[6-(dimethylamino)pyridin-3-yl]-hydroxyboron physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[6-(dimethylamino)pyridin-3-yl]-hydroxyboron Use and application,[6-(dimethylamino)pyridin-3-yl]-hydroxyboron technical grade,usp/ep/jp grade.


Related News: Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. (6-(Dimethylamino)pyridin-3-yl)boronic acid hydrate manufacturer Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. (6-(Dimethylamino)pyridin-3-yl)boronic acid hydrate supplier Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. (6-(Dimethylamino)pyridin-3-yl)boronic acid hydrate vendor Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. (6-(Dimethylamino)pyridin-3-yl)boronic acid hydrate factory However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.